Fundraising FoxNK-One Therapeutics
Wayne, US · Founded 2026 · Delaware corporation
Find your way into NK-One Therapeutics
Sign up to see every warm intro you have to NK-One Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NK-One Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NK-One Therapeutics is a biotechnology company developing a first-in-class intrathecal molecular therapy (SP-SAP) that selectively disables NK-1 receptor pain-signaling neurons in the spine to treat refractory pain in end-stage cancer patients. The therapy is in a Phase 1 clinical trial and is also intended for veterinary use.
Founders & leadership
MP
Marco PappagalloSecretary
MS
Michael ShineChief Executive Officer and President
M
MikeCEO
DP
Dr. PappagalloChief Medical Officer / Medical Advisor
P
PaulDrug Development Lead
Reported raises · per SEC filings
Form D private placements$290K disclosed across 1 round · 2026
▶$290KraisedApr 2026 · 7 investors · BiotechnologyRule 506(b)
▶$290KraisedApr 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marco PappagalloExecutive Officer, Director
- Michael ShineExecutive Officer, Director
- Offering amount
- $310K
- Amount sold
- $290K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2026
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
NKore BiotherapeuticsNKore BioTherapeutics is a cellular-based biotherapeutics company developing an allogeneic immunotherapy platform based on a proprietary method of activating natural killer (NK) cells, called Supercharged NK (sNK) cells. Its lead therapy, NK101, targets solid and blood cancers in adult and pediatric patients, with human clinical trials planned in the United States beginning in 2027.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Nkarta, Inc.Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
Companies working in the same space as NK-One Therapeutics.
Frequently asked questions
- What does NK-One Therapeutics do?
- NK-One Therapeutics is a biotechnology company developing a first-in-class intrathecal molecular therapy (SP-SAP) that selectively disables NK-1 receptor pain-signaling neurons in the spine to treat refractory pain in end-stage cancer patients. The therapy is in a Phase 1 clinical trial and is also intended for veterinary use.
- How much funding has NK-One Therapeutics raised?
- NK-One Therapeutics has disclosed $290K raised across 1 round.
- Where is NK-One Therapeutics headquartered?
- NK-One Therapeutics is headquartered in Wayne, US.